Editorial: New mechanisms and drugs for the treatment of cardiovascular disease with diabetes.
作者信息
Zhang Shanshan, Li Jingwei, Huang Yuli, Yu Jie, Pan Xiong-Fei
机构信息
Section of Epidemiology and Population Health, Ministry of Education Key Laboratory of Birth Defects and Related Diseases of Women and Children, National Medical Products Administration Key Laboratory for Technical Research on Drug Products In Vitro and In Vivo Correlation, West China Second University Hospital, Chengdu, Sichuan, China.
Shuangliu Institute of Women's and Children's Health, Shuangliu Maternal and Child Health Hospital, Chengdu, Sichuan, China.
出版信息
Front Cardiovasc Med. 2023 Feb 20;10:1144858. doi: 10.3389/fcvm.2023.1144858. eCollection 2023.
Abstract
摘要
相似文献
1
Editorial: New mechanisms and drugs for the treatment of cardiovascular disease with diabetes.社论：治疗糖尿病合并心血管疾病的新机制与药物
Front Cardiovasc Med. 2023 Feb 20;10:1144858. doi: 10.3389/fcvm.2023.1144858. eCollection 2023.
2
Effects of SGLT2 Inhibitors on Atherosclerosis: Lessons from Cardiovascular Clinical Outcomes in Type 2 Diabetic Patients and Basic Researches.钠-葡萄糖协同转运蛋白2抑制剂对动脉粥样硬化的影响：来自2型糖尿病患者心血管临床结局及基础研究的经验教训
J Clin Med. 2021 Dec 27;11(1):137. doi: 10.3390/jcm11010137.
3
Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis.钠-葡萄糖共转运蛋白 2 抑制剂与其他降糖药物治疗 2 型糖尿病患者的心血管死亡率和发病率（CVD-REAL Nordic）：一项多国观察性分析。
Lancet Diabetes Endocrinol. 2017 Sep;5(9):709-717. doi: 10.1016/S2213-8587(17)30258-9. Epub 2017 Aug 3.
4
Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: The potential contribution to diabetes complications and cardiovascular disease.钠-葡萄糖协同转运蛋白 2 抑制剂对全身和组织低度炎症的影响：对糖尿病并发症和心血管疾病的潜在贡献。
Diabetes Metab. 2018 Dec;44(6):457-464. doi: 10.1016/j.diabet.2018.09.005. Epub 2018 Sep 26.
5
Cardiovascular Benefit of SGLT2 Inhibitors in the Therapeutics of Diabetes Mellitus: A Close Look beyond the Horizon.钠-葡萄糖协同转运蛋白 2 抑制剂在糖尿病治疗中的心血管获益：超越地平线的深入观察。
Curr Drug Targets. 2018;19(9):1051-1057. doi: 10.2174/1389450119666180531102227.
6
Impact of sodium glucose cotransporter-2 inhibitors on liver steatosis/fibrosis/inflammation and redox balance in non-alcoholic fatty liver disease.钠-葡萄糖共转运蛋白 2 抑制剂对非酒精性脂肪性肝病肝脂肪变性/纤维化/炎症及氧化还原平衡的影响。
World J Gastroenterol. 2022 Jul 14;28(26):3243-3257. doi: 10.3748/wjg.v28.i26.3243.
7
Inhibition of sodium-glucose cotransporter 2 to slow the progression of chronic kidney disease.抑制钠-葡萄糖共转运蛋白 2 以减缓慢性肾脏病的进展。
Acta Clin Belg. 2022 Aug;77(4):805-814. doi: 10.1080/17843286.2021.1966583. Epub 2021 Aug 17.
8
Autophagy-dependent and -independent modulation of oxidative and organellar stress in the diabetic heart by glucose-lowering drugs.降糖药物通过自噬依赖性和非依赖性途径调节糖尿病心脏的氧化应激和细胞器应激。
Cardiovasc Diabetol. 2020 May 13;19(1):62. doi: 10.1186/s12933-020-01041-4.
9
How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials.SGLT2（钠-葡萄糖共转运蛋白 2）抑制剂和 GLP-1（胰高血糖素样肽-1）受体激动剂如何降低心血管结局？：已完成和正在进行的机制试验。
Arterioscler Thromb Vasc Biol. 2020 Mar;40(3):506-522. doi: 10.1161/ATVBAHA.119.311904. Epub 2020 Jan 30.
10
Can we go beyond surrogates?我们能否超越代理人？
J Diabetes. 2017 Nov;9(11):976-977. doi: 10.1111/1753-0407.12583.
本文引用的文献
1
SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials balancing their risks and benefits.SGLT2 抑制剂在 2 型糖尿病中的应用：心血管结局试验风险与获益平衡的系统评价和荟萃分析。
Diabetologia. 2022 Dec;65(12):2000-2010. doi: 10.1007/s00125-022-05773-8. Epub 2022 Aug 4.
2
Association of uterine fibroids with increased blood pressure: a cross-sectional study and meta-analysis.子宫肌瘤与血压升高的关联：一项横断面研究及荟萃分析。
Hypertens Res. 2022 Apr;45(4):715-721. doi: 10.1038/s41440-022-00856-w. Epub 2022 Feb 15.
3
Heart Disease and Stroke Statistics-2022 Update: A Report From the American Heart Association.《心脏病与卒中统计-2022 更新：美国心脏协会报告》。
Circulation. 2022 Feb 22;145(8):e153-e639. doi: 10.1161/CIR.0000000000001052. Epub 2022 Jan 26.
4
Comparison Between the Performance of Quantitative Flow Ratio and Perfusion Imaging for Diagnosing Myocardial Ischemia.定量血流比与灌注成像诊断心肌缺血的性能比较。
JACC Cardiovasc Imaging. 2020 Sep;13(9):1976-1985. doi: 10.1016/j.jcmg.2020.02.012. Epub 2020 Apr 15.
5
2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD.2019年欧洲心脏病学会（ESC）与欧洲糖尿病研究协会（EASD）合作制定的糖尿病、糖尿病前期和心血管疾病指南。
Eur Heart J. 2020 Jan 7;41(2):255-323. doi: 10.1093/eurheartj/ehz486.
6
Evaluation of Coronary Artery Stenosis by Quantitative Flow Ratio During Invasive Coronary Angiography: The WIFI II Study (Wire-Free Functional Imaging II).经皮冠状动脉介入治疗术中定量血流比评估冠状动脉狭窄：WIFI II 研究（无导线功能成像 II）。
Circ Cardiovasc Imaging. 2018 Mar;11(3):e007107. doi: 10.1161/CIRCIMAGING.117.007107.
7
Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes.二甲双胍对心血管疾病的影响：一项对 2 型糖尿病患者随机试验的荟萃分析。
Diabetologia. 2017 Sep;60(9):1620-1629. doi: 10.1007/s00125-017-4337-9. Epub 2017 Aug 2.
8
Early Detection and Treatment of the Vulnerable Coronary Plaque: Can We Prevent Acute Coronary Syndromes?易损冠状动脉斑块的早期检测与治疗：我们能否预防急性冠状动脉综合征？
Circ Cardiovasc Imaging. 2017 May;10(5). doi: 10.1161/CIRCIMAGING.116.005973.
9
Clinical management of dilated cardiomyopathy: current knowledge and future perspectives.扩张型心肌病的临床管理：当前认知与未来展望
Expert Rev Cardiovasc Ther. 2016;14(2):137-40. doi: 10.1586/14779072.2016.1125292. Epub 2015 Dec 14.
10
Pyroptosis: host cell death and inflammation.细胞焦亡：宿主细胞死亡与炎症反应
Nat Rev Microbiol. 2009 Feb;7(2):99-109. doi: 10.1038/nrmicro2070.
Zotero 插件